DETAILED ACTION
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant’s submission filed on May 11, 2026 has been entered.
The indicated allowability of claim 31 is withdrawn in view of newly discovered references. Rejections based on these newly cited references follow.
Claim Objections
Claim 18 is objected to because of the following informalities: On page 6, line 2, please replace “Ru is H” with “R11 is H”.
Claim 18 is objected to because of the following informalities: On page 6, line 6, please replace “Ru is C1-C3” with “R11 is C1-C3”.
Claim 20 is objected to because of the following informalities: In line 3, please insert “of formula” after “monomer”.
Claim 20 is objected to because of the following informalities: In line 4, please insert “of formula” after “monomer”.
Claim 31 is objected to because of the following informalities: On page 8, line 22, please replace “Ru is H” with “R11 is H”.
Claim 31 is objected to because of the following informalities: On page 8, line 25, please replace “Ru is C1-C3” with “R11 is C1-C3”.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim 31 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Choi et al. (KR 10-2016-0044877).
Example 4 in Table 1 of Choi et al. discloses a composition comprising 20 wt % of acryloylmorpholine, 10 wt % of tris(2-hydroxyethyl)isocyanurate triacrylate, 10 wt % of tetrahydrofurfuryl acrylate, and 5 wt % of photoinitiator.
Claim 31 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Cai et al. CN 109912753).
Example 1 of Cai et al. discloses a composition comprising 43.23 wt % of acryloylmorpholine, 19.21 wt % of tris(2-hydroxyethyl)isocyanurate triacrylate, 9.6 wt % of 1,6-hexanediol diacrylate, and 1.92 wt % of photoinitiator.
Allowable Subject Matter
Claims 1, 2, 4, 6-12, 14, 23-25, and 28-30 are allowed for the same reasons elucidated in the notice of allowance dated February 25, 2026. Claims 18 and 20 will be allowed upon revisions to overcome claim objections, supra.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rip A. Lee whose telephone number is (571)272-1104. The examiner can be reached on Monday through Friday from 9:00 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Jones, can be reached at (571)270-7733. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/RIP A LEE/Primary Examiner, Art Unit 1762 May 15, 2026
